Myeloma UK Launches New Clinical Trial to Develop Therapies for High-Risk Myeloma
Myeloma UK has launched a new clinical trial to identify the best treatment options for myeloma patients classified as high-risk. The study is the…
News
Venclexta, Velcade, and Dexamethasone Combo Shows Promising Results in Multiple Myeloma Trial
Adding Venclexta (venetoclax) to Velcade (bortezomib) and dexamethasone has shown promising effectiveness and an acceptable safety profile in multiple myeloma patients who progressed during or…
Amiloride, an Old Diuretic Therapy, Can Kill Multiple Myeloma, Spanish Researchers Find
An old blood-pressure-lowering therapy known as a diuretic killed multiple myeloma cells in a lab and in mice, including those resistant to current treatments, Spanish researchers…
First Myeloma Patient in Study Treated with New CAR T-Cell Therapy bb21217
The first patient with relapsed/refractory multiple myeloma has been treated with the investigational therapy bb21217, according to the clinical-stage company bluebird bio. The treatment candidate…
Cellectar’s CLR 131 Shows Positive Phase 1 Trial Results for Heavily Treated Myeloma Patients
All three relapsed or refractory multiple myeloma patients in the final group of Cellectar Biosciences‘ Phase 1 trial of CLR 131 benefited from treatment, researchers said.
Acupuncture Helps to Manage Effects of HSCT and Chemo in Myeloma Patients, Study Says
Acupuncture can help ease the nausea and drowsiness that follows an autologous hematopoietic stem cell transplant in  multiple myeloma patients, a new study suggests. These symptoms…
Patient Recruitment Begins for Phase 1 Trial of P-BCMA-101 CAR T-Cell Therapy for Multiple Myeloma
A Phase 1 trial sponsored by Poseida Therapeutics for the company’s investigational CAR T-cell therapy for multiple myeloma, P-BCMA-101, is now enrolling participants. The…
Japanese Regulator Approves Darzalex Combo for Relapsed or Refractory Multiple Myeloma
The Japanese Ministry of Health, Labor, and Welfare has approved Darzalex (daratumumab) in combination with either Revlimid (lenalidomide) and dexamethasone, or Velcade (bortezomib)…
Autolus Advances New Myeloma CAR T-cell Therapy in Clinical Trial
Autolus has successfully completed dosing the first group of patients in a Phase 1/2 trial of AUTO2 — a CAR T-cell therapy that targets two…
Bluebird and Celgene Start an Extension of Phase 1 Trial of Myeloma Therapy bb2121
The developers of the myeloma therapy candidate bb2121 have started an extension study of a Phase 1 clinical trial to continue evaluating its safety and…
Recent Posts
- Germany clears pelareorep pancreatic cancer trial continuation
- FDA grants orphan drug status to novel brain cancer treatment
- Medicaid expansion can raise demand for gynecologic cancer care
- Under-the-skin Sarclisa found as effective as approved formulation
- FDA gives LYT-200 fast track status as potential AML treatment